Advances in Pharmacogenomics-Based Individualized Antithrombotic Therapy for Acute Ischemic Stroke

doi:10.3969/j.issn.1673-5765.2024.10.001

Abstract

Abstract: Antithrombotic therapy is a key measure for preventing acute ischemic stroke recurrence. With the advancement of multi-omics research and the identification of more genes affecting drug safety and efficacy, pharmacogenomics is gaining attention for its role in individualized therapy. This paper reviews the progress of research on pharmacogenomics in guiding antithrombotic therapy for patients with acute ischemic stroke, aiming to elucidate the potential of gene detection in optimizing drug selection and dosage adjustments. Studies have shown that the efficacy of drugs like clopidogrel is modulated by polymorphisms in the cytochrome P450 family 2 subfamily C member 19 (CYP2C19) gene. Patients carrying loss-of-function alleles such as CYP2C19*2 or CYP2C19*3 demonstrate diminished responses to standard antiplatelet therapy and cannot effectively reduce the risk of stroke recurrence. However, gene detection can significantly improve treatment outcomes by guiding drug selection. Additionally, for patients with cardioembolic stroke, warfarin or novel oral anticoagulants are commonly used as primary antithrombotic treatment options. The dosage effects of warfarin are closely related to the polymorphisms in genes such as cytochrome P450 family 2 subfamily C member 9 (CYP2C9) and vitamin K epoxide reductase complex 1 (VKORC1). Gene detection can help physicians individualize warfarin dosing, reducing the occurrence of bleeding or thrombotic events. In conclusion, the application of pharmacogenomics in antithrombotic therapy for acute ischemic stroke provides a new idea for individualized therapy, with the potential to further improve the safety and efficacy in the future.

Key words: Acute ischemic stroke; Pharmacogenomics; Individualized therapy; Antithrombotic therapy

摘要： 抗栓治疗是预防急性缺血性卒中复发的关键手段。随着多组学研究的进展和越来越多影响药物安全性和有效性的相关基因被发现，药物基因组学在个体化治疗中的应用逐渐受到关注。本文阐述了药物基因组学在急性缺血性卒中患者抗栓治疗中的指导作用的研究进展，旨在挖掘通过基因检测优化药物选择与剂量调整的潜力。研究表明，氯吡格雷等药物的疗效因细胞色素P450酶家族2亚家族C成员19（cytochrome P450 family 2 subfamily C member 19，CYP2C19）基因多态性而异，携带CYP2C19*2或CYP2C19*3等功能缺失等位基因的患者对标准抗血小板治疗反应较差，不能有效降低卒中复发风险，但通过基因检测指导药物选择可以显著提高治疗效果。此外，心源性卒中患者目前常选择华法林或新型口服抗凝药作为主要的抗栓治疗选择。华法林的剂量效应与多个基因，如细胞色素P450酶家族2亚家族C成员9（cytochrome P450 family 2 subfamily C member 9，CYP2C9）和维生素K环氧化物还原酶C1（vitamin K epoxide reductase complex 1，VKORC1）的多态性密切相关。基因检测能够帮助医师个体化调整华法林剂量，减少出血或血栓事件的发生。综上所述，药物基因组学在急性缺血性卒中抗栓治疗中的应用为个体化治疗提供了新的思路，未来有望进一步提高治疗的安全性和有效性。

关键词: 急性缺血性卒中; 药物基因组学; 个体化治疗; 抗栓治疗

YANG Jiajie, ZHANG Liang, HUANG Li’an. Advances in Pharmacogenomics-Based Individualized Antithrombotic Therapy for Acute Ischemic Stroke[J]. Chinese Journal of Stroke, 2024, 19(10): 1111-1117.

杨佳洁, 张亮, 黄立安. 基于药物基因组学的急性缺血性卒中个体化抗栓治疗进展[J]. 中国卒中杂志, 2024, 19(10): 1111-1117.

References

[1] ZHOU M G，WANG H D，ZENG X Y，et al. Mortality，morbidity，and risk factors in China and its provinces，1990—2017：a systematic analysis for the global burden of disease study 2017[J]. Lancet，2019，394（10204）：1145-1158.
[2] TU W J，CHAO B H，MA L，et al. Case-fatality，disability and recurrence rates after first-ever stroke：a study from bigdata observatory platform for stroke of China[J/OL]. Brain Res Bull，2021，175：130-135[2024-06-08]. https://doi.org/10.1016/j.
brainresbull.2021.07.020.
[3] XU J，ZHANG X，JIN A M，et al. Trends and risk factors associated with stroke recurrence in China，2007—2018[J/OL]. JAMA Netw Open，2022，5（6）：e2216341[2024-06-08]. https://doi.org/10.1001/jamanetworkopen.2022.16341.
[4] BANGAD A，ABBASI M，DE HAVENON A. Secondary ischemic stroke prevention[J]. Neurotherapeutics，2023，20（3）：721-731.
[5] WEINSHILBOUM R M，WANG L W. Pharmacogenetics and pharmacogenomics：development，science，and translation[J/OL]. Annu Rev Genomics Hum Genet，2006，7：223-245[2024-06-08]. https://doi.org/10.1146/annurev.genom.6.
080604.162315.
[6] PIRMOHAMED M. Pharmacogenomics：current status and future perspectives[J]. Nat Rev Genet，2023，24（6）：350-362.
[7] WANG Y J，WANG Y L，ZHAO X Q，et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med，2013，369（1）：11-19.
[8] JOHNSTON S C，EASTON J D，FARRANT M，et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA[J]. N Engl J Med，2018，379（3）：215-225.
[9] SAIZ-RODRÍGUEZ M，BELMONTE C，CANIEGO J L，et al. Influence of CYP450 enzymes，CES1，PON1，ABCB1，and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention[J]. Clin Ther，2019，41（6）：1199-1212. e2.
[10] PAN Y S，WANGQIN R Q，LI H，et al. F2R polymorphisms and clopidogrel efficacy and safety in patients with minor stroke or TIA[J/OL]. Neurology，2021，96（1）：e1-e9[2024-06-08]. https://doi.org/10.1212/WNL.0000000000011078.
[11] PAN Y，CHEN W，WANG Y，et al. Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack：secondary analysis of a randomized clinical trial[J]. JAMA Neurol，2019，76（5）：552-560.
[12] PEREIRA N L，RIHAL C S，SO D Y F，et al. Clopidogrel pharmacogenetics[J/OL]. Circ Cardiovasc Interv，2019，12（4）：e007811[2024-06-08]. https://doi.org/10.1161/CIRCINTERVENTIONS.119.007811.
[13] BOTTON M R，WHIRL-CARRILLO M，DEL TREDICI A L，et al. Pharmvar genefocus：CYP2C19
[J]. Clin Pharmacol Ther，2021，109（2）：352-366.
[14] SIBBING D，ARADI D，ALEXOPOULOS D，et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention[J]. JACC Cardiovasc Interv，2019，12（16）：1521-1537.
[15] SIBBING D，KOCH W，GEBHARD D，et al. Cytochrome 2C19*17 allelic variant，platelet aggregation，bleeding events，and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation，2010，121（4）：512-518.
[16] ZHOU S F，LIU J P，CHOWBAY B. Polymorphism of human cytochrome P450 enzymes and its clinical impact[J]. Drug Metab Rev，2009，41（2）：89-295.
[17] WANG Y L，ZHAO X Q，LIN J X，et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack[J]. JAMA，2016，316（1）：70-78.
[18] WANG Y L，CHEN W Q，LIN Y，et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack：open label，blinded endpoint，randomised controlled phase Ⅱ trial[J/OL]. BMJ，2019，365：l2211[2024-06-08]. https://doi.org/10.1136/bmj.l2211.
[19] XIE X W，JOHNSTON S C，WANG A X，et al. Association of CYP2C19 loss-of-function metabolizer status with stroke risk among Chinese patients treated with ticagrelor-aspirin vs. clopidogrel-aspirin：a prespecified secondary analysis of a randomized clinical trial[J/OL]. JAMA Netw Open，2023，6（6）：e2317037[2024-06-08]. https://doi.org/10.1001/jamanetworkopen.2023.17037.
[20] JAFRIN S，NAZNIN N E，REZA M S，et al. Risk of stroke in CYP2C19 LOF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy：an ethnicity-based updated meta-analysis[J/OL]. Eur J Intern Med，2021，90：49-65[2024-06-08]. https://doi.org/10.1016/j.ejim.2021.05.022.
[21] WU P，LIU Z Q，TIAN Z J，et al. CYP2C19 loss-of-function variants associated with long-term ischemic stroke events during clopidogrel treatment in the Chinese population[J]. Clin Pharmacol Ther，2023，114（5）：1126-1133.
[22] LIU L P，LI Z X，ZHOU H Y，et al. Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases：executive summary and 2023 update[J/OL]. Stroke Vasc Neurol，2023，8（6）：e3[2024-06-08]. https://doi.org/10.1136/svn-2023-002998.
[23] EPSTEIN R S，MOYER T P，AUBERT R E，et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES（Medco-Mayo warfarin effectiveness study）[J]. J Am Coll Cardiol，2010，55（25）：2804-2812.
[24] KIMMEL S E，FRENCH B，KASNER S E，et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing[J]. N Engl J Med，2013，369（24）：2283-2293.
[25] PIRMOHAMED M，BURNSIDE G，ERIKSSON N，et al. A randomized trial of genotype-guided dosing of warfarin[J]. N Engl J Med，2013，369（24）：2294-2303.
[26] CAVALLARI L H，LANGAEE T Y，MOMARY K M，et al. Genetic and clinical predictors of warfarin dose requirements in African Americans[J]. Clin Pharmacol Ther，2010，87（4）：459-464.
[27] HERNANDEZ W，GAMAZON E R，AQUINO-MICHAELS K，et al. Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans[J]. J Thromb Haemost，2017，15（4）：735-743.
[28] JORGENSEN A L，PRINCE C，FITZGERALD G，et al. Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics：a matched cohort study[J/OL]. BMC Med，2019，17（1）：76[2024-06-08]. https://doi.org/10.1186/s12916-019-1308-7.
[29] GAGE B F，BASS A R，LIN H，et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty：the GIFT randomized clinical trial[J]. JAMA，2017，318（12）：1115-1124.
[30] GUO C X，KUANG Y，ZHOU H H，et al. Genotype-guided dosing of warfarin in Chinese adults：a multicenter randomized clinical trial[J/OL]. Circ Genom Precis Med，2020，13（4）：e002602[2024-06-08]. https://doi.org/10.1161/CIRCGEN.119.002602.
[31] VAN SPALL H G C，WALLENTIN L，YUSUF S，et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries：an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy（RE-LY）trial[J]. Circulation，2012，126（19）：2309-2316.
[32] PERREAULT S，DE DENUS S，WHITE-GUAY B，et al. Oral anticoagulant prescription trends，profile use，and determinants of adherence in patients with atrial fibrillation[J]. Pharmacotherapy，2020，40（1）：40-54.
[33] PROIETTI M，ROMANAZZI I，ROMITI G F，et al. Real-world use of apixaban for stroke prevention in atrial fibrillation：a systematic review and meta-analysis[J]. Stroke，2018，49（1）：98-106.
[34] LIP G Y H，KESHISHIAN A，LI X Y，et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients[J]. Stroke，2018，49（12）：2933-2944.